XML 25 R4.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]        
Net sales $ 1,480.9 $ 1,319.0 $ 4,470.7 $ 4,034.1
Cost of sales 350.4 253.8 1,022.9 822.5
Gross profit 1,130.5 1,065.2 3,447.8 3,211.6
Selling, general, and administrative expenses 439.6 377.3 1,344.6 1,156.6
Research and development expenses 270.3 233.6 801.8 713.0
Intellectual property agreement and litigation expense (income), net (Note 3) 2.2 (2.4) 193.6 10.8
Change in fair value of contingent consideration liabilities (Note 8) 0.0 (12.5) (26.2) (36.3)
Special charge (Note 4) 0.0 66.8 0.0 66.8
Operating income, net 418.4 402.4 1,134.0 1,300.7
Interest income, net (15.1) (6.9) (32.8) (8.4)
Other (income) expense, net (5.8) 2.0 (9.6) 1.0
Income before provision for income taxes 439.3 407.3 1,176.4 1,308.1
Provision for income taxes 55.6 63.8 146.7 184.6
Net income 383.7 343.5 1,029.7 1,123.5
Net loss attributable to noncontrolling interest (Note 7) (1.2) 0.0 (2.8) 0.0
Net income attributable to Edwards Lifesciences Corporation $ 384.9 $ 343.5 $ 1,032.5 $ 1,123.5
Earnings per share:        
Basic (in dollars per share) $ 0.63 $ 0.55 $ 1.70 $ 1.81
Diluted (in dollars per share) $ 0.63 $ 0.55 $ 1.69 $ 1.79
Weighted-average number of common shares outstanding:        
Basic (in shares) 607.0 619.8 607.2 621.0
Diluted (in shares) 609.5 624.5 610.2 626.9